1. Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria.
- Author
-
Zhao, Aiping, Zhang, Ke, Wang, Zhen, Ye, Kaihe, Xu, Zhaosi, Gong, Xiao, and Zhu, Guanghu
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *MEDICAL information storage & retrieval systems , *PREDICTION models , *RESEARCH funding , *QUESTIONNAIRES , *TREATMENT duration , *META-analysis , *QUANTITATIVE research , *DESCRIPTIVE statistics , *CHRONIC diseases , *MONOCLONAL antibodies , *SYSTEMATIC reviews , *MEDLINE , *DOSE-effect relationship in pharmacology , *DRUG efficacy , *URTICARIA , *ONLINE information services , *CONFIDENCE intervals , *EVALUATION - Abstract
Purpose: Several studies have shown that subcutaneous injections of omalizumab can treat chronic idiopathic/spontaneous urticaria (CIU/CSU) patients by only assessing the efficacy on specific endpoints. This study aimed to quantitatively analyze different doses of omalizumab in CIU/CSU and compare it with ligelizumab. Methods: Literature searches were performed in PubMed, Embase, and Web of Science databases. A model-based meta-analysis (MBMA) was utilized to develop a model incorporating time since the initiation of treatment and dose for omalizumab, with the change from baseline in Urticaria Activity Score (CFB-UAS7) as the primary efficacy endpoint. The time-course and dose-effect relationship throughout the omalizumab treatment period was analyzed, and the findings were compared with those of the investigational ligelizumab. Results: The model equation for the CFB-UAS7 was established as E = –Emax × time/(ET50 + time) × (b0 + b1 × dose). The estimated values of the model parameters E max , ET 50 , b 0 , and b 1 were −1.16, 1.26 weeks, −9.90, and −0.0361 mg−1, respectively. At week 12 after the first dose, the model-predicted CFB-UAS7 for 150 mg and 300 mg of omalizumab were −16.0 (95% CI, −17.2 to −14.8) and −21.7 (95% CI, −22.9 to −20.5), respectively. In the PEARL-1 trial, the CFB-UAS7 for 72 mg and 120 mg of ligelizumab were −19.4 (95% CI, −20.7 to −18.1) and −19.3 (95% CI, −20.6 to −18.0), respectively. In the PEARL-2 trial, these values were −19.2 (95% CI, −20.5 to −17.9) and −20.3 (95% CI, −21.6 to −19.0), respectively. Conclusion: Omalizumab showed a significant dose-dependent effect in the treatment of CSU. Both 72 mg and 120 mg ligelizumab might have the potential to outperform 150 mg (but not 300 mg) omalizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF